Speakers

Rox Anderson, MD, is Professor in Dermatology, Director of the Wellman Center for Photomedicine, and Professor of Health Sciences and Technology at MIT. Dr. Anderson conceived and developed many of the non-scarring laser treatments now widely used in dermatology. These include selective photothermolysis for birthmarks, microvascular and pigmented lesions, tattoo and permanent hair removal. He also contributed to laser lithotripsy, laser angioplasty, photodynamic therapy, infrared confocal microscopy. Dr. Anderson has contributed to basic knowledge of human photobiology, drug photosensitization mechanisms, tissue optics, and laser-tissue interactions. Dr. Anderson graduated from MIT, received his MD degree magna cum laude from the joint MIT-Harvard medical program, Health Sciences and Technology, and completed his residency in dermatology and research fellowships at Harvard. Dr. Anderson has been awarded over 50 national and international patents. He is a trustee of Advancing Innovation in Dermatology.

Howard Murad, MD, is recognized as a leading visionary for his scientific innovations and founder of the Inclusive Health movement, which focuses on a total body approach to youth building and overall wellness. His mission and passion is to help people unlock their potential to look younger, to feel younger and to live healthier, happier and more rewarding lives. By sharing his scientific discovery of The Science of Cellular Water™, which identifies the common denominator of aging and illness as cellular water loss, he empowers people to achieve whole-body wellness, effortless weight management and freedom from stress—the keys to living well and aging well.

A board certified dermatologist, trained pharmacist and Associate Clinical Professor of Medicine at the Geffen School of Medicine, UCLA, Dr. Murad has personally treated over 50,000 patients. In 1989 – 25 years ago -- he founded Murad, Inc., as a way to share his groundbreaking skincare formulas, which were among the first to achieve significant measurable anti-aging results without surgery. Dr. Murad continues his innovative research and holds 19 patents for advances in the science of skin health.

Known as “The Father of Internal Skincare” for being an originator of the use of dietary supplements to promote skin health and as the pioneer of the use of Alpha Hydroxy Acids in topical skin care, Dr. Murad has received numerous recognitions including “The Aesthetic Visionary Award for Lifetime Achievement” from The Aesthetic Show – (an award that is now called the “Howard Murad, MD Visionary Award”).

He continues his innovative research today using his training as a pharmacist and a physician, his insights as an entrepreneur and his enormous passion for life to positively transform overall health and wellness of people across the globe. He is in the process of launching a new study in conjunction with UCLA and the VA Greater Los Angeles to determine the positive effects of his whole body treatment approach on veterans struggling with PTSD.

His latest book, Conquering Cultural Stress, will be released in January of 2015.

Dr. Shanler is the Chief Scientific Officer at Aclaris. He is a Board Certified dermatologist and dermatologic/Mohs micrographic surgeon. Prior to co-founding Aclaris, Dr. Shanler was a co-founder and Chief Scientific Officer of Vicept Therapeutics (acquired by Allergan in 2011) and was co-inventor of the Vicept technology. Dr. Shanler also co-founded Aspect Pharmaceuticals, a dermatology specialty (development stage) pharmaceutical company, where he served as CEO and Chief Medical Officer.

Dr. Shanler received a dual B.A. degree in Biology (comparative vertebrate physiology), and the Biological Basis of Behavior from the University of Pennsylvania from which he was graduated with Honors & Distinction in Research for work performed on cytochrome oxidase. He received his MD degree from the Albany Medical College of Union University where he received the Albert M. Yunich Award for clinical excellence in Medicine. He completed residency in Internal Medicine at the Beth Israel Medical Center of New York and then served as attending physician and clinical instructor in Internal Medicine at Elmhurt General Hospital and the Mount Sinai School of Medicine.

Dr. Shanler completed residency in Dermatology at the State University of New York at Buffalo and served as Fellow in Cutaneous Oncology and Investigational Laser Therapeutics/Photodynamic Therapy (PDT) at the Roswell Park Cancer Institute where his research focused on PDT and the development of topical and systemic drug/laser systems for the treatment of various skin cancers. He then served as Assistant Clinical Professor of Dermatology at Roswell Park prior to returning to Philadelphia where he completed an ACMS approved fellowship in Mohs micrographic surgery & dermatologic surgery under the direction of Dr. Anthony Benedetto.

Dr. Shanler has received numerous awards for his clinical research, has presented his research and lectured at local, national, and international conferences, and has co-written, edited, and contributed to numerous peer reviewed articles and textbook chapers over the last 20 years

Dr. Ivor Caro is a Senior Medical Director at Genentech, Inc. in South San Francisco working in the fields of dermatology and skin cancer.

A native of South Africa, Dr. Caro completed his medical and dermatology training there. He left South Africa in 1974 and completed a fellowship at St Johns' Hospital for Diseases of the Skin in London. He came to the US in 1975 and served as an Assistant Professor in Dermatology at the University of North Carolina before moving to Seattle in 1978. He was the Chief of the Section of Dermatology, Virginia Mason Medical Center in Seattle and was a Clinical Professor of Dermatology at the University of Washington.

Prior to joining Genentech, he was the Director of the Dermatology Clinical Investigations Unit of the Massachusetts General Hospital, Department of Dermatology, Harvard Medical School. He also served as the Director of the International Training Program in Dermatology, Department of Dermatology, Harvard Medical School and was an Assistant Professor of Dermatology at Harvard.

Dr. Caro is a Fellow of the American Academy of Dermatology and has served on a number of committees in this organization. He was the Secretary/Treasurer and the President of the Noah Worcester Dermatological Society, a national dermatology society and has served on their Board of Trustees and has been the Scientific Chairman. He has memberships in other dermatology societies including the Society for Investigative Dermatology. He is certified by the American Board of Dermatology. He has authored or co-authored over 50 publications.

Ervin Epstein, MD, joined the Children's Hospital Oakland Research Institute (CHORI) in May, 2007 after 35 years at UCSF. He graduated from Harvard College, UCSF Medical School, and received his subsequent clinical dermatology and research training at Washington University of St Louis, Harvard, New York University, and the National Institutes of Health. Since 1972 he has divided his time between independent private practice of Dermatology in Oakland and Lafayette and independent research into the molecular bases of skin diseases. He has authored more than 100 published papers and, among other organizational posts, has been the President of the Society for Investigative Dermatology, the world’s largest organization devoted to investigation of the skin and its diseases. He has delivered numerous named award lectureships including those honoring Sulzberger (the American Academy of Dermatology) and Dohi (the Japanese Dermatologic Association) and was the 2005 recipient of a Lifetime Achievement Award from the American Skin Association.

His current NIH-funded research focuses on non-melanoma skin cancers, in particular the commonest human cancer - basal cell carcinomas. He and others identified a crucial molecular abnormality driving the development and maintenance of these tumors a decade ago and subsequently has focused on adopting this new information into therapies that someday might make surgical extirpation obsolete. In addition his lab is investigating the cell of origin of these tumors, characterizing the cancer stem cells that perpetuate their growth, determining why some people are so much more susceptible to their growth than are others, even if of the same skin coloration, the role of the immune system in inhibiting their growth, and the development not only of new treatments but also of effective preventive approaches.

Jim has been with Technology Partners since 2002. Jim leads the firm's efforts in Consumer Medicine, investing in both medical device and biopharmaceutical companies.

He serves on the boards of Essentialis, ForSight VISION5, Revance Therapeutics (RVNC), Transcend Medical, and TRIA Beauty, while also having led Technology Partners' investment in companies that have since been acquired: Iomai (IOMI - acquired by Intercell AG), Cadence Pharmaceuticals (CADX - acquired by Mallinkrodt), Incline Therapeutics (acquired by The Medicines Company - MDCO). Jim is also an advisor to the Lester Center at University of California, Berkeley and the National Science Foundation (NSF) in Washington, DC.

Previously, Jim was Managing Director at CIT Venture Capital, leading the group's effort in Life Science investing. Also, Jim was a leader within McKinsey & Company's Pharmaceutical and Medical Products Practice. Jim earned a BS from Duke University and an MA and a PhD from Harvard University in biology. He was a Deutsche Akademische Austauschdienst (DAAD) fellow at Universitaet des Saarlandes, Germany and a post-doctoral fellow at University of California, Berkeley. Jim has published several research papers and had his research highlighted in major media outlets including: Nature, The New York Times, Scientific American, and CNN.

Andrew Hall joined Celgene in 2014 to lead the development of Celgene’s Immunology pipeline as the Commercial head of New Products and Strategic Analytics.

Prior to joining Celgene, Andrew led product development for Women’s Health at Merck (MSD outside of the US) and over the span of 15 years has held leadership roles in Emerging Markets, Japan, Australia and Malaysia. He has extensive experience in Global Commercial Strategy, Drug Development, End to End Lifecycle Management as well as Mergers, Acquisitions and Business Development.

Andrew holds a Masters of Marketing from Melbourne Business School and a Bachelor or Medicine (medical science Honors) from Melbourne University in Australia.

Jon Hanifin is a board-certified dermatologist who received his medical degree from the University of Wisconsin Medical School-Madison in 1965. He interned at San Francisco General Hospital and then received specialty training in dermatology from the University of California-San Francisco, where he also completed an NIH research fellowship in the Division of Hematology/Immunology. He joined the OHSU faculty in 1971, where his academic work includes clinical practice, research, and education.

He is an international lecturer and recognized expert in the research and treatment of atopic dermatitis. He has directed a number of national and international symposia on this subject and was a founding member of the International Society of Atopic Dermatitis (ISAD). Dr. Hanifin served on the Board of the National Psoriasis Foundation for 15 years, the Board of Directors of the Society for Investigative Dermatology from 1988-1991, and the Board of Directors of the American Academy of Dermatology from 1998-2002. In 1988 he helped to found the National Eczema Association, serving as President until 1990 and continues on the Board of Directors.

Dr. Hanifin has received many honors, including the Royal Society of Medicine Visiting Professor, Burroughs Wellcome Traveling Lectureship, London 1989-1990, the Dohi Memorial Lectureship from the Japanese Dermatological Association in 1994, and the American Academy of Dermatology Master Dermatologist in 2007. Dr. Hanifin has published more than 276 peer-reviewed articles and has contributed chapters to many textbooks.

Doug Ingram is a senior executive in the pharmaceutical, medical device, and biologics space with a proven track record of consistently delivering above-market sales/earnings results, and developing and leading transformational and highly profitable strategies and initiatives.

In his most recent position as President of Allergan, Inc., he was responsible for the company’s worldwide commercial performance. In 2014, he led a restructuring and strategic plan enhancement that reduced expenses by $575 million, enhanced sales growth, greatly improved earnings growth, and generated approximately $20 billion in shareholder value on a forward PE basis, while driving in 2014 the best sales and earnings performance in Allergan’s 64-year history.

As President of Allergan Europe/Middle East/Africa Region (EMEA) from 2010 to 2013, Mr. Ingram restructured the region, upgraded talent, and managed through a pan-regional recession to drive significantly above-market growth in sales and contribution margin, leading all regions in performance.

Doug joined Allergan in 1996 and rapidly took on increasing responsibilities, joining the Company’s Executive Committee, reporting to the CEO and serving the Allergan Board as Secretary by 2001 and leading numerous global functions, including Legal, Regulatory, Safety, Public Relations/Corporate Communications, IT, Human Resources, Audit, and Compliance. Over time, the strategies he helped develop and the initiatives he led transformed the company and fueled its consistent top-quartile growth over the 2000s: the spin-out of Allergan’s ophthalmology medical device and solutions business as Advanced Medical Optics, Inc. (AMO) in 2002, giving birth to a robust ophthalmic device company while unlocking Allergan's ability to focus its time, energy and resources on its high margin, high growth pharmaceutical and biologics strategy; the $3 billion acquisition of Inamed by Allergan in 2006 that transformed the company into the worldwide leader in Medical Aesthetics; the defence of Allergan against Department of Justice allegations (2008–2010), including the filing of a first-of-its-kind lawsuit against the United States to establish the industry’s First Amendment rights, leading to a favourable settlement and articulating arguments that have been subsequently used by pharmaceutical companies to establish rights to disseminate truthful, non-misleading information about drugs and devices in the United States.

Before Allergan, Doug was an associate at Gibson, Dunn & Crutcher LLP, where he focused on complex commercial litigation. He has been a Board Member of Volcom, Inc., ECC Capital, and is a Board Member of OC Marathon (also a founding member, former Co-Chairman, and current limited liability partner), and the California Healthcare Institute (CHI).

He holds a Bachelor of Science, magna cum laude, from Arizona State University, and a Doctor of Law (J.D.), summa cum laude and Order of the Coif, from the University of Arizona, James E. Rogers College of Law.

Dr. Mark Lebwohl graduated summa cum laude from Columbia College in 1974 and graduated from Harvard Medical School in 1978. He completed residencies in internal medicine and dermatology, both at Mount Sinai.

Dr. Lebwohl has been practicing dermatology since 1983. He is professor and chairman of the Department of Dermatology of The Icahn School of Medicine at Mount Sinai. Dr. Lebwohl has served as president of the New York Dermatological Society, the Manhattan Dermatologic Society, and the New York State Society of Dermatology, and as chairman of the Dermatology Section of the New York Academy of Medicine. Dr. Lebwohl is the 2014-15 President- Elect of the American Academy of Dermatology, and will serve as the AAD President in 2015-16.

Dr. Lebwohl is Chairman Emeritus of the Medical Board of the National Psoriasis Foundation. He is the founding editor of Psoriasis Forum and is on the editorial boards of the Journal of the American Academy of Dermatology and the Journal of Skin Cancer. He is also editor of the Dermatology Section of Scientific American Medicine. Dr. Lebwohl has chaired numerous symposia and has written, edited, or co-edited several books including the first atlas devoted entirely to cutaneous manifestations of systemic disease, and the leading book on dermatologic therapy, Treatment of Skin Disease which is now in its 4th edition. The second edition of The Skin and Systemic Disease has been published in English and in French, and English, Portuguese, Chinese and Polish versions of Treatment of Skin Disease have been published. Other books include Difficult Diagnoses in Dermatology, Psoriasis, Mild-to-Moderate Psoriasis and Moderate-to-Severe Psoriasis. Dr. Lebwohl is actively involved in clinical trials of many new dermatologic treatments. He has authored or co-authored over 500 publications including peer-reviewed articles, invited articles and book chapters.

Dr. Lebwohl has received numerous awards for teaching, research, mentorship and service from the Mount Sinai School of Medicine, the American Academy of Dermatology, the National Psoriasis Foundation, PXE International, the American Skin Association, the Journal of Drugs in Dermatology, the Royal Society of Medicine, and the President’s Council on Service and Civic Participation.

Didier C. Leclercq is the Managing Director for SHIELD, the Nestle Skin Health Education, Investigation and Longevity Development network.

The SHIELD network is a Nestle Skin Health Initiative aiming at creating an environment and providing means for Health Care Professionals and social workers to create the framework of the tomorrow care.

Nestle Skin Health is one of the world’s largest companies dedicated to supporting healthcare professionals and meeting the needs of patients seeking medical solutions to their skin, hair and nail conditions.

After joining Galderma R&D in 2003 Didier took increasing responsibilities in different parts of the world up to the full responsibility for Global Development for the company. During the last three years Didier took over the Managing director responsibility for Q-Med AB in Sweden a leading company in the field of Aesthetic and Corrective acquired by Galderma in 2011.

Didier has scientific degrees in Chemistry, has a passion for Life Sciences and has continuously acquired knowledge and expertise all along his career first at Pfizer, then at Wyeth-Ayerst and finally at Galderma.

Dr. Douglas Lowy is Deputy Director of the National Cancer Institute (NCI), National Institutes of Health (NIH), and Chief of the Laboratory of Cellular Oncology in the Center for Cancer Research at NCI. He received his medical degree from New York University School of Medicine, and trained in internal medicine at Stanford University and dermatology at Yale. Dr. Lowy's research includes the biology of papillomaviruses and the regulation of normal and neoplastic growth. The papillomavirus research is carried out in close collaboration with Dr. John Schiller, with whom he has co-authored more than 125 papers over the past 30 years. In the 1980s, they studied the genetic organization of papillomaviruses and identified the oncogenes encoded by the virus. More recently, they have worked on papillomavirus vaccines and the papillomavirus life cycle. Their laboratory was involved in the initial development, characterization, and clinical testing of the preventive virus-like particle-based HPV vaccines that are now used in the three FDA-approved HPV vaccines. Dr. Lowy's growth regulation research includes prior studies that established the importance of the ras gene family in cancer and the main mechanisms by which the NF1 tumor suppressor gene regulates normal cell growth. His growth regulation research is now focused primarily on the DLC family of tumor suppressor genes and their mechanism of action. Dr. Lowy is a member of the National Academy of Sciences (NAS) and of the Institute of Medicine of the NAS. For their pioneering work, he and Dr. Schiller have received numerous honors, including the 2007 Federal Employee of the year Service to America Medal from the Partnership for Public Service, the 2011 Albert B. Sabin Gold Medal Award, and the 2012 National Medal of Technology & Innovation (awarded in 2014). Dr. Lowy has also received the National Medal of Honor for Basic Research from the American Cancer Society as well as awards from the American Academy of Dermatology, the Society for Investigative Dermatology, and the American Skin Association.

Markham has served as a Deputy Office Director in the Office of Device Evaluation (ODE), Center for Devices and Radiological Health, FDA since 2008. In this capacity he works with the management and staff in the review Divisions in fulfilling the missions of the Office. He supervises and works with the CDRH Advisory Panel Coordinator on Medical Device Advisory Committee meetings, and serves as ODE's interface to the Office of Compliance (OC), Office of Surveillance and Biometrics (OSB), and the CDRH ExecSec. He is the Office supervisory liaison for the Medical Countermeasure, Emergency Preparedness, and Internal Communication programs. ODE conducts premarket review of cutting edge therapeutic and diagnostic device technologies. This component of the FDA evaluates the safety and effectiveness of new medical devices prior to their introduction into the marketplace. Markham has research interests in clinical study design, clinical endpoints assessment, and scale development (including patient-reported outcomes) for medical, surgical, and aesthetic products. Markham is a strong advocate for medical device development for rare diseases and special populations. He has interfaced with CDRH Staff College on developing reviewer training initiatives, and has been a preceptor and mentor for the FDA Commissioner's Fellows Program since 2009.

Markham was born and raised in New York City where he attended Stuyvesant High School, and majored in Biochemistry at New York University. He attended medical school at Johns Hopkins University for his MD degree, and studied under Professor Donald S. Coffey for his PhD in Pharmacology and Molecular Sciences. Markham was an internal medicine intern at the Johns Hopkins Bayview Medical Center, Baltimore, Maryland and a dermatology resident at Washington University/Barnes Hospital, St. Louis, Missouri. He served as PHS Fellow and Clinical Associate for Dermatology at the National Cancer Institute, NIH, beginning in 1997, followed by service as a Medical Officer reviewer at FDA, Center for Drug Evaluation and Research (CDER). In 2001, he was selected as Lead Medical Officer for Dermatology drug products. While at CDER, he was involved in various review and regulatory initiatives for dermatology drugs, in addition to serving as consultant dermatologist for other parts of FDA. He also serves as an attending dermatologist at Bethesda National Naval Medical Center (now the Walter Reed Medical Center - WRMC), where he cares for dermatology patients (adult and pediatric) and teaches residents and medical students. Markham continues to participate in weekly dermatology instructional and patient care activities at WRMC and NIH. See more

When it comes to understanding the patent landscape in the life sciences, there are very few patent lawyers more experienced than Mika Mayer. She has become one of the most sought-after patent lawyers in the medical device, drug delivery, and pharmaceutical fields. In addition to preparing and prosecuting patent applications, she provides strategic patent portfolio analysis for her clients. She works extensively in performing both investor-side and company-side IP due diligence reviews. The potential investments she has overseen range in size from small seed investments to multi-billion-dollar acquisitions in the medical device, drug delivery, and pharmaceutical fields. Ms. Mayer is also often relied upon to assist with some of the firm's litigation matters involving technologies within her areas of expertise.

Ms. Mayer develops IP strategies and prosecutes patent applications with a laser focus on protecting her clients' interests and maximizing their value and commercial success. Her prosecution and due diligence engagements have helped her clients shore up their patent portfolios and raise capital to further develop their technologies. She led the IP due diligence for Gilead Sciences' acquisition of YM Biosciences as well as the IP due diligence for Astellas Pharmaceutical's $4 billion hostile takeover of OSI Pharmaceuticals. In all, Ms. Mayer has participated in, or led, more than 400 IP due diligence reviews for some of the most sophisticated health care companies and investors in the world.

Ms. Mayer is consistently called upon by top decision makers in the medical device, drug delivery, and pharmaceutical communities for her ability to translate IP risks into business risks, and provide strategic guidance and oversight in this regard. As these industries have gone global, so has her practice, with companies around the world utilizing her expertise.

She is a guest lecturer for Stanford's Biodesign Innovation Class, a current member of the Science Accelerator Committee of the American Heart Association, and a board member of the Women in Law Empowerment Forum.

Raymond A. Miller is co-chair of Pepper Hamilton’s Intellectual Property Transactions and Rights Management Practice Group, and resides in the Pittsburgh office. He also is a member of the firm’s Executive Committee. Mr. Miller is a key element of Pepper’s life science practice. He has spent his career identifying, protecting, securing and maximizing intellectual property in the biotechnology and life science areas.

Mr. Miller’s clients range from academic institutions to world-class medical and research facilities. His clients have included physicians, venture capital groups, start-up biotechnology companies, Fortune 500 Companies and leading dermatology companies. Mr. Miller is particularly experienced in the areas of chemistry, medicinal chemistry, genetics, pharmaceuticals, nutraceuticals, proteonomics, nanotechnology, tissue engineering, surface chemistry, dermatology and cosmetics.

Although Mr. Miller’s practice focuses on corporate intellectual property transactions and strategic counseling, he has been involved in all facets of intellectual property, including: handling litigation, licensing and settlement negotiations; preparing, filing and securing patents throughout the world; rendering legal opinions on issues of patentability, inventorship, ownership, infringement, invalidity, enforceability and freedom to operate; assisting venture capital and investment groups in evaluating biotechnology and life science opportunities; advising on the interplay of regulatory exclusivity and patent law on cosmetic, pharmaceutical, nutraceutical and medical device products; managing diverse patent portfolios and invention disclosure programs to document and protect inventions through patent, trade secret and copyright laws; counseling drug companies on unique patent issues relating to drug development, including Orange Book listing, label claims, patent term restoration and extension, and subtle issues of written description, enablement, genus and species, anticipation and obviousness in the “unpredictable arts”; negotiating complex technology transfer, license, asset purchase, and merger agreements; and providing patent coverage analysis for commercial products.

Mr. Miller is himself an inventor on two issued patents: U.S. Patent No. 8,563,609, assigned to Nitromega Corp., entitled “Nitro Fatty Acids –Neuroprotection and Inhibition of Cognitive Decline, and U.S. Patent No. 8,686,167, entitled “Heteroatom Containing Substituted Fatty Acids,” assigned to Complexa, Inc. Mr. Miller co-founded both Complexa & Nitromega. Complexa is an emerging pharmaceutical company with a product in clinical trials, and Nitromega is a dietary supplement company.

Mr. Miller has extensive experience representing dermatology concerns, including current or former representation of Aspect Pharmaceuticals; Allergan, Skin Type Solutions; Valeant Pharmaceuticals; Vicept Therapeutics; Aclaris Therapeutics; Medisys, Inc.; Fibrocell Sciences, Inc.; NOX Technologies, and NuSkin. He was one of the architects of the oxymetazoline patent strategy for Aspect/Vicept/Allergan, and was the lead attorney in negotiating the sale of the intellectual property developed around NuSkin’s commercially successful over-the-counter ageLOC product line.

Mr. Miller is a 1988 graduate of the University of Akron, where he earned a bachelor’s degree in chemistry, and a 1990 graduate of Princeton University, where he earned his master’s degree in organic chemistry. Mr. Miller received his law degree from Case Western Reserve University School of Law in 1994. He is admitted to practice before the U.S. Patent & Trademark Office, the state and federal courts of Pennsylvania and Ohio, and the U.S. Court of Appeals for the Federal Circuit.

Jeffrey K. Mills, PhD is a partner in the Washington, D.C. office of Fanelli Haag & Kilger. His practice focuses on pharmaceutical, drug delivery, nanotechnology, biotechnology, materials and medical device matters. Dr. Mills has extensive legal experience in patent prosecution, licensing, due diligence and opinion work, as well as experience in litigation support and interference proceedings.

Prior to joining the firm, Dr. Mills spent over seven years as a technical specialist, student associate and then as an associate at a leading D.C. intellectual property boutique. Dr. Mills has presented at international meetings on nanotechnology-related legal topics including freedom-to-operate, enablement and obviousness issues facing innovators in this technical area.

He has also published and presented extensively in the areas of drug delivery and biological materials characterization.

Dr. Mills graduated from Duke University (B.S.E. in biomedical engineering; certificate in genetics) and received his PhD in mechanical engineering and materials science, also from Duke University.

He received his J.D. from the George Washington University Law School, with honors. Dr. Mills is admitted to practice before the U.S. Patent and Trademark Office and in Virginia and the District of Columbia.

Cami Samuels joined Venrock in 2014 and focuses on healthcare with an emphasis on biotech and consumer health. Prior to Venrock, Cami was a Managing Director at Versant Ventures for a decade where she led investments in Achaogen (AKAO), Kythera (KYTH), Novacardia (acquired by Merck), and ParAllele (acquired by Affymetrix), among others. She was also a board observer at several companies including Genomic Health (GHDX), Fluidigm (FLDM), and Syrrx (acquired by Takeda).

Before Versant, she was responsible for business development at Tularik, Inc. (acquired by Amgen) where she in-licensed two of the company's clinical-stage products and led Tularik's Technology Acquisition Group. Before Tularik, Cami worked in corporate development at Genzyme and Millennium Predictive Medicine, and was a management consultant to healthcare and biotech companies at LEK Consulting.

Cami earned her Bachelor's degree in Biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar. In 2002, The Aspen Institute named Camille a Henry Crown Fellow.

Jean Tang, MD, PhD is an Associate Professor of Dermatology at the Stanford University Medical Center. Her research focuses on finding new ways to treat and prevent non-melanoma skin cancer. Jean and her colleagues showed that Hedgehog pathway inhibition could dramatically shrink Basal Cell Carcinoma tumors in patients with Gorlin Syndrome in randomized clinical trials. They have also repurposed itraconazole and other drugs for BCC treatment in preclinical models and in clinical trials.

Patricia Walker, MD, PhD, currently serves on the board of directors for Neothetics, Inc., and she actively consults for global pharmaceutical companies. Dr. Walker's professional experience includes her position as Chief Medical Officer of Kythera Biopharmaceuticals, Inc., from May 2007 until March 2013. Then, from 2004 to 2007, Dr. Walker served as Executive Vice President and Chief Science Officer at Allergan Medical (formerly known as Inamed Corporation). Prior to that experience, from 1997 to 2004, Dr. Walker held positions of increasing responsibility at Allergan Inc., a biomedical company, where she ultimately served as Vice President, Clinical Research and Development for skin care pharmaceuticals.

Over the past 10 years, Dr. Walker was involved in key product approvals in dermatology and aesthetic medicine including the development and approval of Tazorac®, Azelex®, Avage®, BOTOX® Cosmetic, Hylaform®, Captique®, JUVEDERM®, Bioenterics®, LAP-BAND®, and Inamed® Silicone gel-filled Breast Implants. Dr. Walker received her doctor of medicine (MD) degree and her doctor of philosophy (PhD) degree in Physiology and Biophysics from the University of Iowa. Dr. Walker completed a residency in Dermatology and a research fellowship in the Dermatology Branch of the National Cancer Institute at the National Institutes of Health. Dr. Walker is a board-certified Dermatologist.

Dr. Walker is an independent consultant and the immediate past director of the Division of Dermatology and Dental Products (DDDP) at the Food and Drug Administration. From 2006 – 2014 she led this division of over 40 senior physicians, scientists and staff with responsibilities for review of New Drug Applications, Biologics Licensing Applications, Investigational New Drug Applications, labeling supplements, Pediatric Study Plans, Risk Evaluation and Mitigation Strategies and other regulatory submissions. Responsibilities also included oversight of the divisions meetings with industry regarding both pre and post market issues; advisory committee preparation; drafting, editing and implementation of guidances; and leading various cross-discipline and cross-center teams.

Dr. Walker is a fellow of the American Academy of Dermatology, a member of the American Dermatological Association, and is board certified in Dermatology (1990). She has an active medical license in Maryland. Before going to FDA she was Chief of the Dermatology Section at the VA in Martinez, CA.

Dr. Walker's experience includes18 years at FDA serving in multiple leadership positions across FDA Centers, including medical reviewer, Lead Medical Officer, and Division Director (DDDP) in the Center for Drug Evaluation and Research (CDER); detail as acting deputy director in the Division of General, Reconstructive, and Neurological Devices the Center for Devices and Radiologic Health (CDRH); Associate Director for Clinical Affairs in the Office of Nutritional Products, Labeling, and Dietary Supplements; and Director of the Division of Dietary Supplement Programs in the Center for Food Safety and Nutrition (CFSAN).

Dr. Walker received her BS from the University of Michigan and her MD from the Uniformed Services University School of Medicine, and served as a medical officer in the US Navy with several ship deployments and service with the US Marine Corps.

Dr. Walker currently provides independent consulting services as Susan J. Walker Consulting, LLC.

Jonathan K. Wilkin, MD, the founding director (retired) of the Division of Dermatology and Dental Products at the US Food and Drug Administration, remains active in regulatory matters after over 12 years of FDA service which included membership on the FDA’s Dermatology Drugs Advisory Committee. Before going to the FDA, he was Director of Dermatology at the Ohio State University and Professor of Pharmacology and Medicine. He has over 130 publications in dermatology and clinical pharmacology.

Dr. Wilkin received his BA and MS in zoology from Ohio State University in Columbus, followed by his medical degree from the Ohio State University College of Medicine. After a year of residency in obstetrics and gynecology at the University of Louisville, School of Medicine in Kentucky, he completed a residency in dermatology at the University of Tennessee Health Science in Memphis, where he was Chief Resident.

Dr. Wilkin has served as chairman of the medical advisory board for the National Rosacea Society from 1998 to 2012 as well as having chaired their Expert Committees on the Classification and Staging System for Rosacea. He also has served on the American Academy of Dermatology’s (AAD) Ad Hoc Task Force on the Academy’s Efforts with FDA and on their Environment and Drugs Committee. Dr. Wilkin has been active in the American Society for Clinical Pharmacology and Therapeutics, having chaired the Dermatologic and Allergic Diseases Section and the Constitution and By-laws Committee for several years, as well as serving in other capacities.

Dr. Wilkin is a fellow of the AAD, a member of the American Dermatological Association and board certified by both the American Board of Dermatology and the American Board of Clinical Pharmacology.

Lee T. Zane, MD, is a board-certified dermatologist and Anacor’s Senior Vice President and Chief Medical Officer. He had served as Anacor's Vice President of Clinical Development from August 2008 to October 2013 and had served as Medical Director at Anacor since January 2008. From 2003 to 2007, Dr. Zane served as Assistant Professor of Clinical Dermatology at the University of California, San Francisco (UCSF), Department of Dermatology, where he was the Director of Mt. Zion Dermatology Clinical Research Unit and the Director of the Acne Specialty Practice.

Dr. Zane received his Bachelor of Arts (BA) degree (valedictorian; summa cum laude) with high honors in Neuroscience from Colgate University and his Doctor of Medicine (MD) degree from Stanford University. He completed his Dermatology residency training at UCSF, where he also earned a Master of Advanced Studies (MAS) degree in Clinical Research and maintains a faculty position as Assistant Clinical Professor of Dermatology.